Within the inflammatory response cascade, CXCR3 promotes the migration of T lymphocytes from the blood to tissues at the site of inflammation. These white blood cells contribute to the amplification of tissue damage and disease progression, and the hope is that blocking this cell traffic will reduce inflammation and pain in diseases such as multiple sclerosis, inflammatory bowel disease and psoriasis.
Scientists at BioXell and at The University of Modena in Italy havepreviously identified the CXCR3 receptor as a molecule associated with the inflammatory process underlying chronic obstructive pulmonary disease (COPD).
By combining their respective expertise and resources, the two companies will work towards identifying and developing orally active, small molecular weight CXCR3 antagonists with a more selective mechanism of action and a better safety profile than currently available therapies.
Under the terms of the agreement, BioXell will contribute its know-how and biological in vitro and in vivo models, while Zambon will provide its chemical library, screening facilities and experience in drug optimisation. BioXell and Zambon will share all revenues derived from the development of any compound resulting from the agreement.